CXCL8 and colonic neoplasm: Huang et al. [103] reported the use of PASS web resources for the validation of MYC/CXCL8 (C-X-C motif chemokine ligand 8)/TIMP1 (TIMP metallopeptidase inhibitor 1) oncogenes, which regulate immune response in an antitumor direction by mediating PD-L1, as potential drug targets for RV59 (57), an anthraquinone derivative with anticancer activity against NCI human colon cancer cell lines (Figure 13).